• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticles use 2 mechanisms to boost immunotherapy

June 12, 2017 By Sarah Faulkner

Nanoparticle immunotherapy
Credit: ACS Nano

Cancer immunotherapy, a treatment approach that has gained momentum over the past few years, only helps a small fraction of patients. But researchers from the Johns Hopkins University School of Medicine have developed a nanoparticle that may one day help expand the patient population that benefits from immunotherapy.

Immunotherapy usually falls into 1 of 2 categories: it either prevents cancer cells from hiding from the patient’s immune system or it stimulates the body’s T cells to fight against tumors. The team from Johns Hopkins hoped to devise a nanoparticle platform that could do both.

To accomplish that, the researchers developed “immunoswitch” nanoparticles which simultaneously turn off a pathway on tumor cells that would otherwise render the tumor invisible to the immune system and turn on a specific T cell process that triggers them to fight cancer cells.

The team evaluated its nanoparticle technology in mouse models of melanoma and colon cancer. The animals injected with the nanoparticles lived longer than those that were not treated. In some cases, the animals’ tumor growth was delayed or even reversed following treatment with the team’s immunoswitch particles.

In the study, up to half of the mice in 1 cancer group experienced full remission after the treatment.

The team also reported that they were able to use low concentrations of treatment, which could help alleviate the severe side effects characteristic of dual immunotherapy.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: Johns Hopkins

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS